Epidermal growth factor (EGF) A61G polymorphism and EGF gene expression in normal colon tissue from patients with colorectal cancer

References

• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127–37
   PubMed Web of Science ®Google Scholar
• Lockhart C, Berlin JD. The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin Oncol 2005; 32: 52–60
   PubMed Web of Science ®Google Scholar
• Gleave ME, Hsieh JT, Wu HC, Hong SJ, Zhau HE, Guthrie PD, et al. Epidermal growth factor receptor-mediated autocrine and paracrine stimulation of human transitional cell carcinoma. Cancer Res 1993; 53: 5300–7
   PubMedGoogle Scholar
• Tyagi P. Recent results and ongoing trials with panitumumab (ABX-EGF), a fully human anti-epidermal growth factor receptor antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 2005; 5: 21–3
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues PJ, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123–32
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337–45
   PubMed Web of Science ®Google Scholar
• Calvo E, Rowinsky EK. Clinical experience with monoclonal antibodies to epidermal growth factor receptor. Curr Oncol Rep 2005; 7: 96–103
   PubMedGoogle Scholar
• Saltz LB, Meropol NJ, Loehrer PJ, Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201–8
   PubMed Web of Science ®Google Scholar
• Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803–10
   PubMed Web of Science ®Google Scholar
• Nagahara H, Mimori K, Ohta M, Utsunomiya T, Inoue H, Barnard GF, et al. Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin Cancer Res 2005; 11: 1368–71
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129–39
   PubMed Web of Science ®Google Scholar
• Spindler KL, Nielsen JN, Lindebjerg J, Brandslund I, Jakobsen A. Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. Int J Radiat Oncol Biol Phys 2006; 66: 500–4
   PubMed Web of Science ®Google Scholar
• Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, Strange RC, et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 2002; 359(9304)397–401
   PubMed Web of Science ®Google Scholar
• Bhowmick DA, Zhuang Z, Wait SD, Weil RJ. A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease. Cancer Res 2004; 64: 1220–3
   PubMedGoogle Scholar
• Zhang W, Gordon M, Press OA, Rhodes K, Vallbohmer D, Yang DY, et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenet Genomics 2006; 16: 475–83
   PubMed Web of Science ®Google Scholar
• Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 2005; 23: 1365–9
   PubMed Web of Science ®Google Scholar
• Lindebjerg J, Nielsen JN, Hoeffding LD, Bisgaard C, Brandslund I, Jakobsen A. Expression of thymidylate synthase in primary colorectal adenocarcinoma. Appl Immunohistochem Mol Morphol 2006; 14: 37–41
   PubMedGoogle Scholar
• Spindler KL. Epidermal growth factor receptor analyses in colorectal cancer. A comparison of methods. Int J Oncol 2006; 29: 1159–65
   PubMed Web of Science ®Google Scholar
• Amend KL, Elder JT, Tomsho LP, Bonner JD, Johnson TM, Schwartz J, et al. EGF gene polymorphism and the risk of incident primary melanoma. Cancer Res 2004; 64: 2668–72
   PubMed Web of Science ®Google Scholar
• James MR, Hayward NK, Dumenil T, Montgomery GW, Martin NG, Duffy DL. Epidermal growth factor gene (EGF) polymorphism and risk of melanocytic neoplasia. J Invest Dermatol 2004; 123: 760–2
   PubMed Web of Science ®Google Scholar
• McCarron SL, Bateman AC, Theaker JM, Howell WM. EGF +61 gene polymorphism and susceptibility to and prognostic markers in cutaneous malignant melanoma. Int J Cancer 2003; 107: 673–5
   PubMed Web of Science ®Google Scholar
• Okamoto I, Roka F, Krogler J, Endler G, Kaufmann S, Tockner S, et al. The EGF A61G polymorphism is associated with disease-free period and survival in malignant melanoma. J Invest Dermatol 2006.
   Google Scholar
• Randerson-Moor JA, Gaut R, Turner F, Whitaker L, Barrett JH, Silva IS, et al. The relationship between the epidermal growth factor (EGF) 5′UTR variant A61G and melanoma/nevus susceptibility. J Invest Dermatol 2004; 123: 755–9
   PubMed Web of Science ®Google Scholar
• Schneider S, Park DJ, Yang D, El Khoueiry A, Sherrod A, Groshen S, et al. Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation. Pharmacogenet Genomics 2006; 16: 555–63
   PubMedGoogle Scholar
• Odin E, Wettergren Y, Nilsson S, Willen R, Carlsson G, Spears CP, et al. Altered gene expression of folate enzymes in adjacent mucosa is associated with outcome of colorectal cancer patients. Clin Cancer Res 2003; 9(16 Pt 1): 6012–9
   Google Scholar